by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
19/4/2021
March 2021 Review of news from the most innovative therapeutic areas and the business development transactions.
SOTIO Research Laboratory, Prague
Market
The Nasdaq Biotech Index lost 14 % since its peak in February 2021
After the constant long-term growth of Nasdaq Biotech Index, a significant drop was seen in February and March. The index lost 14 % compared to its February peak, which is the worst drop in a year. Rising interest rates and investors’ refocus on 2020 down-beaten industries could be a reason.
Prostate Cancer
EMA’s CHMP recommended approval of Xtandi for castration sensitive prostate cancer
The EMA’s CHMP has recommended approval of enzalutamide (Xtandi) for the treatment of adult men with metastatic castration-sensitive prostate cancer.
Ovarian Cancer News
Rucaparib extends PFS in BRCA mutated cancer, except of BRCA reverse mutation
Rucaparib extends PFS in BRCA-mutated OVCA, with an exception of BRCA reverse mutation. PARP inhibitor rucaparib significantly improved PFS compared with chemotherapy in women with BRCA-mutated, advanced, relapsed OVCA in Phase 3 ARIEL4.
Lung Cancer News
FDA expands approval of Lorbrena for ALK positive metastatic lung cancer
FDA expands approval of Lorbrena for ALK-positive metastatic lung cancer. FDA expanded the approval of lorlatinib to include the first-line treatment of adults with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. The FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to detect ALK for treatment with lorlatinib.
Sdílet na sociálních sítích